Gilead Sciences, Inc. $GILD Shares Acquired by Vinva Investment Management Ltd

Vinva Investment Management Ltd lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,886 shares of the biopharmaceutical company’s stock after purchasing an additional 8,713 shares during the period. Vinva Investment Management Ltd’s holdings in Gilead Sciences were worth $9,616,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of GILD. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in Gilead Sciences in the 4th quarter valued at about $215,000. XTX Topco Ltd boosted its stake in shares of Gilead Sciences by 76.8% during the 1st quarter. XTX Topco Ltd now owns 9,156 shares of the biopharmaceutical company’s stock worth $1,026,000 after purchasing an additional 3,976 shares during the last quarter. Brucke Financial Inc. acquired a new position in shares of Gilead Sciences in the first quarter valued at approximately $244,000. Finally, Arkadios Wealth Advisors lifted its stake in shares of Gilead Sciences by 94.6% during the first quarter. Arkadios Wealth Advisors now owns 45,750 shares of the biopharmaceutical company’s stock valued at $5,126,000 after buying an additional 22,240 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. Rothschild & Co Redburn lifted their price objective on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Royal Bank Of Canada upped their target price on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research note on Friday, October 31st. BMO Capital Markets set a $135.00 price target on Gilead Sciences in a research note on Tuesday. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.65.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 115,146 shares of company stock worth $14,012,141. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $127.51 on Thursday. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The stock has a market capitalization of $158.20 billion, a P/E ratio of 25.40, a PEG ratio of 0.81 and a beta of 0.32. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The business’s fifty day moving average price is $119.36 and its 200 day moving average price is $114.25.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.